

Relationship Between Neonatal Adrenomedullin and Serum Bilirubin Levels

Thesis

Submitted in partial fulfillment of the Master Degree (M.Sc.) in
PEDIATRICS

By

Ola Adel Mohammed Ragheb Ghannam

(M.B., B.Ch.)

Resident of Pediatrics

Faculty of Medicine, Cairo University

Under Supervision of

Prof. Dr. Mostafa Zakaria

Professor of Pediatrics

Faculty of Medicine, Cairo University

Dr. Walaa Ahmed Rabie

Assistant Professor of Clinical and Chemical Pathology

Faculty of Medicine, Cairo University

Dr. Dina Mohammed Akmal

Lecturer of Pediatrics

Faculty of Medicine, Cairo University

FACULTY OF MEDICINE

CAIRO UNIVERSITY

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَقُلْ رَبِّ زِدْنِي عِلْمًا

صدق الله العظيم
سورة طه ، الآية: 114

Acknowledgement

First, and foremost, all thanks and gratitude to GOD, to whom I relate any success I have reached & might reach in the future.

*I am greatly honored to express my sincere gratitude & appreciation to **Prof. Dr. Mostafa Zakaria**, Professor of Pediatrics, Faculty of Medicine, Cairo University, for his meticulous supervision, loyal encouragement & valuable advice throughout the work.*

*I would like to express my deepest appreciation to **Dr. Dina Mohammed Akmal**, Lecturer of Pediatrics, Faculty of Medicine, Cairo University, for her remarkable suggestions & close supervision, which were behind the fruitful outcome of all this work.*

*I would like to express my deepest thanks to **Dr. Walaa Ahmed Rabie**, Assistant Professor of Chemical Pathology, Faculty of Medicine, Cairo University, for her meticulous and remarkable effort in the laboratory part of this work.*

Finally, I would like to give many thanks to my father, my mother and all my family members who gave me great & faithful support to finish this work.

Ola Adel Mohammed Ragheb Ghannam

TO MY FAMILY

Abstract

In this study the correlation between serum bilirubin and AM levels was investigated in a total of 80 newborns divided into two groups according to the serum bilirubin levels. Group I (with significant hyperbilirubinemia) and Group II (without significant hyperbilirubinemia

Results: there is a high statistically significant increase in serum adrenomedullin levels in study group (group I) and control group (group II) with levels of 42.538 ± 12.452 and 30.588 ± 11.5902 respectively ($p < 0.001$).

Conclusion: The study concluded that Adrenomedullin probably plays a significant role in adverse effects and neuronal injury steps of significant hyperbilirubinemia.

Keywords:

Hyperbilirubinemia, Adrenomedullin, Bilirubin Neurotoxicity, Neonates

Contents

	PAGE
▪ Abstract.....	v
▪ List of Figures	vii
▪ List of Tables	ix
▪ Abbreviations	x
▪ Introduction	1
▪ Aim of The Work	3
▪ Review of Literature	4
○ Chapter ONE: Neonatal Hyperbilirubinemia	4
○ Chapter TWO: Bilirubin Encephalopathy	24
○ Chapter THREE: Adrenomedullin	35
▪ Patients and Methods	44
▪ Results	49
▪ Discussion	65
▪ Conclusion & Recommendations	70
▪ Summary	71
▪ References	73
▪ Arabic Summary	83

List of Figures

NO.	TITLE	PAGE
1	Neonatal bile pigment metabolism	6
2	Nomogram for designation of risk among 2840 well newborns at ≥ 36 weeks gestation and birth weight ≥ 2000 g, or at ≥ 35 weeks' gestation and birth weight ≥ 2500 g, based on the hour-specific serum bilirubin values	15
3	Bilisphere 360, Novos medical system, Turkey	17
4	Guidelines for phototherapy in hospitalized infants of 35 or more weeks' gestation	18
5	Guidelines for exchange transfusion in infants 35 or more weeks' gestation	21
6	Macroscopic image of brain with yellow staining in globi pallidi. T2 FLAIR coronal MRI of the same case	25
7	Infant with posticteric sequelae of acute bilirubin encephalopathy	29
8	Comparison of study group (group I) and control group (group II) with respect to gender	49
9	Comparison of study group (group I) and control group (group II) with respect to Mode of delivery	50
10	Comparison of study group (group I) and control group (group II) with respect to type of feeding	51
11	Comparison of study group (group I) and control group (group II) with respect to receiving phototherapy treatment	52
12	Comparison of study group (group I) and control group (group II) with respect to presence of a sibling who received phototherapy treatment	53
13	Maternal blood groups of study group (group I) and control group (group II)	54
14	Paternal blood groups of study group (group I) and control group (group II)	56

NO.	TITLE	PAGE
15	Blood groups of newborns in study group (group I) and control group (group II)	58
16	Comparison of study group (group I) and control group (group II) with respect to age in hours, order of parity, maternal age, gestational age, age of sampling age of start of phototherapy and duration of phototherapy	60
17	Anthropometric data of study group (group I) and control group (group II)	61
18	Apgar score in 1 st and 5 th minutes of study group (group I) and control group (group II)	62
19	Biochemical data of study group (group I) and control group (group II)	63
20	Comparison of study group (group I) and control group (group II) with respect to serum Adrenomedullin levels	64

List of Tables

NO.	TITLE	PAGE
1	Risk factors for hyperbilirubinaemia	7
2	Laboratory evaluation of neonatal hyperbilirubinemia	14
3	B/A ratio in infants 35 or more weeks' gestation	22
4	Bilirubin-induced neurological dysfunction (BIND) score	29
5	Modified BIND score	31
6	Hyperbilirubinemia and kernicterus	33
7	Modified BIND score	46
8	Comparison of study group (group I) and control group (group II) with respect to gender	49
9	Comparison of study group (group I) and control group (group II) with respect to Mode of delivery	50
10	Comparison of study group (group I) and control group (group II) with respect to type of feeding	51
11	Comparison of study group (group I) and control group (group II) with respect to receiving phototherapy treatment	52
12	Comparison of study group (group I) and control group (group II) with respect to presence of a sibling who received phototherapy treatment	53
13	Maternal blood groups of study group (group I) and control group (group II)	54
14	Paternal blood groups of study group (group I) and control group (group II)	55
15	Blood groups of newborns in study group (group I) and control group (group II)	57
16	Comparison of study group (group I) and control group (group II) with respect to age in hours, order of parity, maternal age, gestational age, age of sampling age of start of phototherapy and duration of phototherapy	59

LIST OF TABLES

NO.	TITLE	PAGE
17	Anthropometric data of study group (group I) and control group (group II)	61
18	Apgar score in 1 st and 5 th minutes of study group (group I) and control group (group II)	62
19	Biochemical data of study group (group I) and control group (group II)	63
20	Comparison of study group (group I) and control group (group II) with respect to serum Adrenomedullin levels	64

Abbreviations

7TM	Seven Trans membrane
AAP	American Academy of Pediatrics
ABE	Acute bilirubin encephalopathy
ACTH	Adrenocorticotrophic hormone
ALI	Acute lung injury
AM	Adrenomedullin
AN/AD	Auditory neuropathy/dys-synchrony
B/A ratio	The bilirubin/albumin ratio
BBB	Blood brain barrier
BIND	Bilirubin induced neurologic dysfunction
BPD	Bronchopulmonary dysplasia
cAMP	Cyclic adenosine monophosphate
CEC	Cerebral endothelial cells
CGRP	Calcitonin gene-related peptide
CNS	Central nervous system
CRLR, now known as CL	Calcitonin-receptor-like receptor
ET	Exchange transfusion
G6pD:	Glucose-6-phosphate dehydrogenase
GPCR	G-protein-coupled receptor
HDN	Hemolytic Disease of the Newborn
HIE	Hypoxic ischemic encephalopathy
IB	Indirect bilirubin
IgG	Immunoglobulin G
IVH	Intraventricular hemorrhage
IVIG	Intravenous immunoglobulin
NICU	Neonatal Intensive Care Unit

NNPT	Neonatal Phototherapy
NO	Nitric oxide
RAMP	Receptor activity modifying protein
RBC	Red Blood Cell
SnMP	Tin mesoporphyrin
TB	Total bilirubin
TcB	Transcutaneous bilirubin,
TEER	Transendothelial electrical resistance
TNF- α	Tumor necrosis factor
TSB	Total serum bilirubin,
UCB	Unconjugated bilirubin
UCB:Bf	Unbound (free) fraction
UGTs	Uridine diphosphoglucuronosyltransferase

INTRODUCTION

Bilirubin toxicity remains a significant problem despite recent advances in the care of jaundiced (hyperbilirubinemic) neonates. In Cairo University Children's Hospital, severe neonatal hyperbilirubinemia accounted for 33% of total admissions to the out born Neonatal Intensive Care Unit (NICU) in 2006 with 10 cases of kernicterus occurring each year (*Iskander et al., 2012*).

In term infants, acute bilirubin encephalopathy with marked hyperbilirubinemia presents with a sequence of poor suckling, stupor, hypotonia progressing to hypertonia with neck or back arching & diminishing tone (*Kamei et al., 2012*).

Total serum bilirubin in neonatal hyperbilirubinemia (NH) can be above 20mg/dl without neonatal bilirubin encephalopathy (NBE) happening. Moreover, the symptoms of some patients with NBE can be subtle. Using only clinical presentation to differentiate patients with NBE from those with only NH is quite difficult in the neonatal period (*Wu et al., 2013*).

Human adrenomedullin (AM) is a small hormone of 52 amino acids. It belongs to the amylin/calcitonin gene-related peptide (CGRP) super-family, AM contains a six amino acid ring formed by an internal disulfide bond between residues 16 and 21 (*Larráyoz et al., 2014*). The presence of AM production in both brain tissue and peripheral tissues implies that AM inserts its possible effects on brain tissue via complex mechanisms. Increasing synthesis of endogenous AM as a response in oxidative stress suggests that this peptide has a protective role against organ injury by inhibiting the products of oxidative stress (*Kim et al., 2010*).

AM has subsequently been classified as a neuropeptide, recognizing the peptide's influence within the brain and its regulatory capacity at the blood–brain barrier **(Liverani & Paul, 2013)**. AM decreases endothelial permeability by increasing transendothelial electrical resistance (TEER), and with cAMP increase, it plays an important role in the regulation of this barrier **(Erdinc *et al.*, 2014)**.

Although there are many studies performed about the probable mechanisms of bilirubin neurotoxicity on CNS, the exact mechanisms have not yet been determined. Oxidative stress occurring in newborns with hyperbilirubinemia is believed to trigger major mechanisms leading to neuronal injury on the one hand, and both neuron protective properties of AM and its nature as an intrinsic antioxidant and anti-inflammatory peptide suggest a strong relationship between bilirubin levels and AM on the other hand **(Erdinc *et al.*, 2014)**.

AIM OF THE WORK

The aim of this study is to investigate the relationship between serum bilirubin and an antioxidant, anti-inflammatory and neuroprotective peptide, adrenomedullin (AM) levels.